Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

T Brown,1 G Pilkington,1 A Boland,1 J Oyee,1 C Tudur Smith,2 Y Dundar,1 E Richards,3 R Yang4 and R Dickson1*

1Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
2Department of Biostatistics, University of Liverpool, Liverpool, UK
3Clatterbridge Centre for Oncology, Clatterbridge Road, Bebington, Wirral, UK
4Institute of Population Research, Peking University, Beijing, China

*Corresponding author

Executive summary

Chemoradiation for adult patients with locally advanced non-small cell lung cancer

Health Technology Assessment 2013; Vol. 17: No. 6
DOI: 10.3310/hta17060

NIHR Journals Library
Executive summary

Background

Lung cancer is the most common cancer in the world and the second most common cancer diagnosed in the UK after breast cancer. In 2008, there were 40,806 new cases of lung cancer diagnosed in the UK, with 32,546 in England and 2403 in Wales. Lung cancer is rarely diagnosed in people < 40 years of age, and 86% of cases occur in people > 60 years. In both men and women, smoking is the primary cause of lung cancer and prognosis is poor. Early-stage lung cancer is often asymptomatic, with two-thirds of patients diagnosed at a late stage.

Non-small cell lung cancer (NSCLC) accounts for approximately 84% of lung cancer cases. It comprises two main histological subgroups: squamous cell carcinoma and non-squamous cell carcinoma. Squamous cell carcinoma accounts for 33% of all NSCLC cases while non-squamous cell carcinoma (including adenocarcinoma and large cell carcinoma) accounts for 29% of NSCLC cases. Approximately 36% of patients have NSCLC that is ‘not otherwise specified’, 1% have carcinoma in situ and 1% have bronchioloalveolar carcinoma.

Patients of interest to this review are those with locally advanced NSCLC who are not suitable for curative surgery or radical radiotherapy (RT) but who are suitable for potentially curative treatment with chemoradiation (CTX-RT). In terms of first-line treatment, National Institute for Health and Clinical Excellence (NICE) guidelines recommend CTX-RT as the treatment of first choice for patients with stage II or III NSCLC who are not suitable for surgery. However, how currently available CTX and RT regimens should be optimally combined within concurrent CTX-RT remains unclear.

Objective

The aim of this study was to evaluate the clinical effectiveness of first-line chemotherapy (CTX) in addition to RT (CTX-RT vs CTX-RT) for adult patients with locally advanced NSCLC (stages IIIA and IIIB). This review aimed to identify the optimal combination of CTX and RT for this group of patients. There are four main types of CTX-RT: combined, concurrent, sequential and consolidation. Studies with at least two CTX-RT treatment arms comprising any CTX-RT including concurrent, sequential, induction/concurrent and concurrent/consolidation treatments were eligible for inclusion in our evidence synthesis.

The Assessment Group conducted this review as part of a larger systematic review of all first-line CTX and CTX-RT treatments for patients with locally advanced or metastatic NSCLC. It was the opinion of the members of the clinical panel for the project that patients with potentially curable disease (e.g. stage IIIA) are different from those who are considered only for palliative treatment of more advanced disease and that therefore the results relating to these former patients should be reported separately.

Methods of the systematic review (clinical effectiveness)

Search strategy

Three electronic databases (MEDLINE, EMBASE and The Cochrane Library) were searched for randomised controlled trials (RCTs) and systematic reviews. MEDLINE and EMBASE were searched from January 1990 to September 2010. The Cochrane Library was searched up to July 2010. In addition, the database of the American Society for Clinical Oncology (ASCO) was searched from 1998 to 2011 to identify any relevant trials from conference abstracts.
Inclusion criteria
The systematic review was guided by the general principles recommended in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. The results of clinical data extraction and quality assessment are summarised in tables and narrative description.

Patient population
Chemotherapy-naive adult patients with locally advanced NSCLC.

Interventions and comparators
Trials that compared any first-line CTX-RT treatment.

Outcomes
Overall survival (OS) and/or progression-free survival.

Data synthesis
Where appropriate, relative treatment effects for OS were estimated using a standard meta-analysis for head-to-head comparisons between interventions based on intention-to-treat (ITT) analyses. Data limitations meant that further analysis or a mixed-treatment comparison (MTC) was not appropriate.

Results
Of the 240 potentially relevant studies that were published post 2000, 19 met the inclusion criteria of the review. The majority of patients within the trials were male and aged between 53 and 64 years and had stage III adenocarcinoma or squamous cell carcinoma and performance status of 0–1.

Twelve trials compared various regimens of sequential, concurrent and consolidation CTX-RT. Five trials compared different types of RT or CTX, one trial compared RT once daily with RT twice daily, and another trial assessed the addition of weekend CTX. In addition, there were different CTX agents and different radiation doses both across and within trials; number of fractions, schedule, intensity and overall treatment time varied between trials.

The Assessment Group performed several direct evidence comparisons (meta-analysis) using data combining induction, sequential, concurrent and consolidation CTX-RT. The results appear to show no statistically significant evidence to support OS advantage for concurrent CTX-RT over sequential CTX-RT. However, when concurrent/consolidation treatments were compared with sequential treatments, the difference in OS was shown to be statistically significant. When sequential CTX-RT was compared with concurrent CTX-RT with or without consolidation, the latter yielded a statistically significant improvement in OS.

In the trials comparing sequential CTX-RT with concurrent CTX-RT, more patients in the concurrent arms tolerated higher doses of RT. Concurrent/consolidation CTX-RT may be easier to tolerate than induction/concurrent CTX-RT. However, concurrent CTX-RT is associated with greater oesophagus toxicity than sequential CTX-RT.

Conclusions
This review identified that the research conducted in the area of CTX-RT was generally of poor quality and suffered from a lack of reporting of all-important clinical findings, including OS. In addition, there were within- and between-trial variations in treatment protocols including in treatment duration, sequencing and length, RT exposure and type of CTX. These wide variations severely limited the combination of trial
results. The trials were too disparate to form any conclusion as to the optimal individual CTX agent or optimal type of RT.

Meta-analyses conducted as part of this review demonstrated a small but statistically significant improvement in OS in patients receiving concurrent/consolidation CTX-RT compared with sequential CTX-RT and statistically significantly improved OS with the use of concurrent CTX-RT (with or without consolidation) over sequential treatment. However, as noted, the variation in treatment protocols and the changes in the diagnostic criteria and staging used in NSCLC mean that the results of comparisons across these trials and with future trials need to be viewed with caution.

**Suggested research priorities**
An overall strategy that provides structure and continuity of research in the area of CTX-RT is required to allow for clear conclusions regarding its effectiveness to be drawn. The focus of primary research should be good methodological quality. Appropriate allocation of concealment and randomisation alongside comprehensive reporting of key outcomes such as OS and health-related quality of life (HRQoL) will enable meaningful synthesis and allow clear conclusions to be drawn.

**Funding**
Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

**Publication**
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA programme findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

For more information about the HTA programme please visit the website: http://www.hta.ac.uk/

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 09/126/02. The contractual start date was in February 2010. The draft report began editorial review in September 2011 and was accepted for publication in June 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library, produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

**Dr Andree Le May**  Chair of NIHR Journals Library Editorial Group

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

**Professor Aileen Clarke**  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Peter Davidson**  Director of NETSCC, HTA, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Dr Tom Marshall**  Reader in Primary Care, School of Health and Population Sciences, University of Birmingham, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

**Professor Ruairidh Milne**  Head of NETSCC, Director of The Wessex Institute, UK

**Professor Jane Norman**  Professor of Maternal and Fetal Health, University of Edinburgh, UK

**Professor John Powell**  Senior Clinical Researcher, Department of Primary Care, University of Oxford, UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professorial Research Associate, University College London, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Editorial contact:** nihredit@southampton.ac.uk